Based on the results of recent large controlled trials, such as Anglo-Scandinavian Cardiac Outcomes Trial or Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension Trial,13,14 a combination of a calcium channel blocker with a drug interfering with the renin-angiotensin system is usually preferred in patients with diabetes mellitus or in those with an accumulation of other metabolic risk factors, which was also observed in our survey. This evidence concerns the gene REN and diabetes mellitus.